Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen
US biotech major Gilead Sciences (Nasdaq: GILD) has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816.
The investigational drug is being evaluated in Phase III clinical studies as part of a single tablet regimen that combines the compound and Sovaldi (sofosbuvir) for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead’s India-based partners to manufacture GS-5816 and the single tablet regimen of Sovaldi/GS-5816, once approved, for distribution in 91 developing countries, which account for 54% of the worldwide population of individuals infected with the hepatitis C virus (HCV). The Sovaldi/GS-5816 regimen would become the first pan-genotypic, all-oral single tablet regimen for HCV.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze